|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US6534524||PF PRISM CV||Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use|| |
(1 year, 6 months from now)
|US8791140||PF PRISM CV||Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals|| |
(7 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10570202||PF PRISM CV||Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer|| |
(11 years from now)
|US10869924||PF PRISM CV||PD-L1 antagonist combination treatments|| |
(13 years from now)
Inlyta is owned by Pf Prism Cv.
Inlyta contains Axitinib.
Inlyta has a total of 4 drug patents out of which 0 drug patents have expired.
Inlyta was authorised for market use on 27 January, 2012.
Inlyta is available in tablet;oral dosage forms.
Inlyta can be used as axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma, in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma.
The generics of Inlyta are possible to be released after 12 January, 2037.
Market Authorisation Date: 27 January, 2012
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advan...
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic